Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2)
Publication
, Conference
Alsina, M; Richardson, PGG; Schlossman, RL; Weber, DM; Coutre, SE; Gasparetto, C; Mukhopadhyay, S; Ondovik, MS; Khan, MH; Paley, CS; Lonial, S
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2013
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2013
Volume
31
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Alsina, M., Richardson, P. G. G., Schlossman, R. L., Weber, D. M., Coutre, S. E., Gasparetto, C., … Lonial, S. (2013). Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 31). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Alsina, Melissa, Paul Gerard Guy Richardson, Robert L. Schlossman, Donna M. Weber, Steven E. Coutre, Cristina Gasparetto, Sutapa Mukhopadhyay, et al. “Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
Alsina M, Richardson PGG, Schlossman RL, Weber DM, Coutre SE, Gasparetto C, et al. Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.
Alsina, Melissa, et al. “Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2).” JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 15, AMER SOC CLINICAL ONCOLOGY, 2013.
Alsina M, Richardson PGG, Schlossman RL, Weber DM, Coutre SE, Gasparetto C, Mukhopadhyay S, Ondovik MS, Khan MH, Paley CS, Lonial S. Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2013
Volume
31
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences